Authors' recommendations: Rationale: Targeted magnetic resonance imaging (MRI)-guided biopsy techniques, such as MRI-guided in-bore (MRI-IB) biopsy, have been developed to increase identification of clinically significant prostate cancer without increasing the detection of clinically nonsignificant tumors. Technology Description: MRI-IB biopsy is a technique that uses MRI images captured in real time and processed by interventional planning software to help insert and confirm the location of biopsy needles into target lesions suspected to be prostate cancer as previously identified by multiparametric MRI (mpMRI). Controversy: MRI-IB biopsies require more resources than systematic 12-core transrectal ultrasonography (TRUS) biopsy. It is currently unclear whether MRIIB biopsy consistently detects clinically significant cancer at a higher rate than systematic TRUS biopsy, and if the use of these additional resources is warranted. Key Questions: Does MRI-IB biopsy provide accurate diagnostic and/or staging information for men with suspected or diagnosed prostate cancer? Does use of MRI-IB biopsy improve patient management or outcomes? Is MRI-IB biopsy safe? Have definitive patient selection criteria been established for MRI-IB-biopsy?

Project Status: Completed

Year Published: 2017

URL for published report: The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=73646

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: Winifred S. Hayes, Inc